In re EpiPen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation
United States District Court, District of Kansas
MDL No. 2785

Keller Rohrback is proud to be co-lead counsel in this important litigation about the pricing of EpiPens.

For the latest case updates, including breaking news about proposed resolution and upcoming trial, see this website:  www.EpiPenClassAction.com

Mylan Settlement Update

Update: March 11, 2022. “We are pleased that the Court preliminarily approved this settlement with the Mylan defendants in the EpiPen indirect purchaser litigation. As we said in our preliminary approval papers, we continue to believe this settlement is an outstanding result for the class.“ – Lynn Sarko (Co-Lead Counsel and managing partner of Keller Rohrback).  Visit EpiPenClassAction.com to learn more.

February 28, 2022: According to Co-Lead Counsel and Managing Partner of Keller Rohrback Lynn Sarko, “Today’s announcement of our $264 million-dollar settlement with Mylan brings the total recovery to EpiPen class members to $609 million.  We urge consumers and third-party payors who paid for EpiPens to visit EpiPenClassAction.com to learn more about today’s settlement.”

Pfizer Settlement Update

On November 17, 2021, the Court entered an order giving final approval to the settlement between Plaintiffs and the Pfizer Defendants. This order and other key case documents are available on the Settlement Administrator’s website EpiPenClassAction.com (see Case Documents tab). Inquiries relating to the settlement can be directed to the Settlement Administrator, A.B. Data, at (877) 221-7632.